Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:EWG NASDAQ:SLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWGiShares MSCI Germany ETF$42.51+0.8%$41.09$37.97▼$44.65$1.45B0.952.37 million shs55,991 shsSLSSELLAS Life Sciences Group$6.45-1.2%$4.98$1.39▼$6.74$1.19B2.247.45 million shs2.03 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWGiShares MSCI Germany ETF+0.52%-3.01%+0.52%-4.09%+3.87%SLSSELLAS Life Sciences Group+25.10%+26.80%+37.18%+83.94%+363.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWGiShares MSCI Germany ETF$42.51+0.8%$41.09$37.97▼$44.65$1.45B0.952.37 million shs55,991 shsSLSSELLAS Life Sciences Group$6.45-1.2%$4.98$1.39▼$6.74$1.19B2.247.45 million shs2.03 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWGiShares MSCI Germany ETF+0.52%-3.01%+0.52%-4.09%+3.87%SLSSELLAS Life Sciences Group+25.10%+26.80%+37.18%+83.94%+363.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEWGiShares MSCI Germany ETF 0.00N/AN/AN/ASLSSELLAS Life Sciences Group 2.00Hold$10.0055.01% UpsideCurrent Analyst Ratings BreakdownLatest BVT, POLR, EWG, and SLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026SLSSELLAS Life Sciences Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/12/2026SLSSELLAS Life Sciences Group Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $10.00(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEWGiShares MSCI Germany ETFN/AN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/A$0.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEWGiShares MSCI Germany ETFN/AN/A17.79N/AN/AN/AN/AN/AN/ASLSSELLAS Life Sciences Group-$26.86M-$0.25N/AN/AN/AN/A-61.95%-54.48%N/ALatest BVT, POLR, EWG, and SLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026SLSSELLAS Life Sciences Group-$0.06-$0.05+$0.01-$0.05N/AN/A3/19/2026Q4 2025SLSSELLAS Life Sciences Group-$0.0633-$0.05+$0.0133-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEWGiShares MSCI Germany ETF$0.671.59%N/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEWGiShares MSCI Germany ETFN/AN/AN/ASLSSELLAS Life Sciences GroupN/A10.7210.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEWGiShares MSCI Germany ETF53.42%SLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipEWGiShares MSCI Germany ETFN/ASLSSELLAS Life Sciences Group1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEWGiShares MSCI Germany ETFN/A34.20 millionN/ANot OptionableSLSSELLAS Life Sciences Group10184.53 million181.95 millionNot OptionableBVT, POLR, EWG, and SLS HeadlinesRecent News About These CompaniesSLS stock hits 4-year high: BlackRock stake boost fuels buzz around looming AML trial readout2 hours ago | msn.comSELLAS Life Sciences to Participate in Upcoming Investor Conferences2 hours ago | globenewswire.comSLS on track to clock best week in over 4 months: Retail divided between stock drop or multibagger status amid upcoming leukemia trial readoutMay 13 at 7:41 PM | msn.comSELLAS rises as Q1 update suggests lead program nears final analysisMay 13 at 2:38 PM | seekingalpha.comSELLAS Life Sciences Nears Pivotal Trial Readout As Leukemia Pipeline ProgressesMay 13 at 10:18 AM | benzinga.comSELLAS Life Sciences surges on earnings beat, trial updateMay 12 at 7:23 PM | investing.comSELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 12 at 4:05 PM | globenewswire.comSELLAS Life Sciences Group (SLS) to Release Earnings on TuesdayMay 10, 2026 | americanbankingnews.comSLS stock heads for weekly win: Deutsche Bank’s stake boost draws attention ahead of Q1 earningsMay 8, 2026 | msn.comSELLAS Life Sciences Group (SLS) Expected to Announce Earnings on TuesdayMay 5, 2026 | marketbeat.comSLS stock kicks off week in green: CEO flags role in EU biotech policy talks that could impact drug approvalsMay 4, 2026 | msn.comSLS stock tests $5 again: Retail targets 'no' vote on 20M share dilution push before AML trial resultsMay 1, 2026 | msn.comSELLAS Life Sciences Group (SLS) price target increased by 15.38% to 10.20April 28, 2026 | msn.comSLS stock jumps overnight: CEO doubles down on ‘steadfast’ confidence in AML drug and pushes for 20M share plan approvalApril 27, 2026 | msn.comSELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up - Still a Buy?April 27, 2026 | marketbeat.comWhy SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Down 6.79%April 26, 2026 | aaii.comASELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 8.1% - Here's WhyApril 24, 2026 | marketbeat.comSellas Life Sciences: 'Hold' As Phase 3 AML Study Progresses To Key EventApril 24, 2026 | seekingalpha.comSellas Life Sciences: Behind The Big SurgeApril 22, 2026 | seekingalpha.comSLS stock jumps premarket: US investor Dagco boosts stake by 78% ahead of fresh cancer drug data revealApril 21, 2026 | msn.comWall Street Analysts Think SELLAS Life Sciences Group, Inc. (SLS) Could Surge 66.09%: Read This Before Placing a BetApril 20, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBVT, POLR, EWG, and SLS Company DescriptionsiShares MSCI Germany ETF NYSEARCA:EWG$42.51 +0.35 (+0.83%) As of 10:17 AM EasterniShares MSCI Germany ETF, formerly iShares MSCI Germany Index Fund (the Fund), is an exchange-traded fund. The Fund seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of publicly traded securities in the German market, as measured by the MSCI Germany Index (the Index). The Index seeks to measure the performance of the Germany equity market. It is a capitalization-weighted index that aims to capture 85% of the (publicly available) total market capitalization. The Fund invests in sectors, such as consumer discretionary, financials, materials, industrials, healthcare, information technology, utilities, telecommunication services and consumer staples. BlackRock Fund Advisors (BFA) serves as the investment adviser to the Fund.SELLAS Life Sciences Group NASDAQ:SLS$6.46 -0.06 (-1.00%) As of 10:35 AM Eastern This is a fair market value price provided by Massive. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? D-Wave Earnings Looked Weak, But Investors May Be Missing This A Quantum Shift: Why Speculative Money Is Ditching AI Plug Power Flips The Switch On Profitability Affirm's Google Deal Aims for Your Wallet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
